Neuralstem (CUR) 1.68 $CUR 6 Stocks Under $10 T
Post# of 273327
Posted On: 07/29/2015 1:27:15 PM
Neuralstem (CUR) 1.68 $CUR
6 Stocks Under $10 Triggering Breakout Trades
at The Street - Thu Jul 23, 1:09PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
MBI: 6.33 (+0.14), MX: 8.45 (-0.17), JASO: 7.67 (+0.25), IDRA: 3.45 (-0.16), NPTN: 8.90 (-0.34), CUR: 1.68 (-0.05)
Court Rules That StemCells, Inc. Lacks Standing to Pursue Patent Infringement Suit
GlobeNewswire - Thu Jul 23, 12:42PM CDT
StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that the Company's patent infringement case, StemCells, Inc. v. Neuralstem, Inc., has been dismissed by the U.S. Federal District Court for the District of Maryland for lack of standing. The judge's decision was based solely on the grounds that a former associate of the named inventors on the six patents in the litigation, Drs. Samuel Weiss and Brent Reynolds, has an interest in the patents because, as a former colleague, he assisted with their early research.
STEM: 0.43 (+0.01), CUR: 1.68 (-0.05)
US District Court Rules In Favor Of Neuralstem In Patent Infringement Case
PR Newswire - Thu Jul 23, 6:45AM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the U.S. District Court for the District of Maryland dismissed StemCells, Inc.'s patent infringement case with prejudice in StemCells, Inc. v. Neuralstem, Inc. in favor of Neuralstem, on July 22, 2015.
CUR: 1.68 (-0.05)
Major Depressive Disorder Pipeline Review, H1 2015 - 37 Companies & 32 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6wpzn/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - Alkermes Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics plc - Edgemont Pharmaceuticals, LLC - Eli Lilly and Company - Euthymics Bioscience, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. Drug Profiles - (aripiprazole sertraline) - (samidorphan buprenorphine hydrochloride) - amitifadine - AN-788 - aripiprazole - AV-101 - AVP-786 - basimglurant - brexpiprazole - bupropion hydrochloride ER - cariprazine - CERC-301 - desvenlafaxine succinate SR - EDG-005 - edivoxetine - esketamine hydrochloride - INASTR-001 - ITI-007 - lurasidone hydrochloride - LY-03005 - LY-2940094 - MIN-117 - miR-135 - MSI-195 - NLF-NEU - NRX-1074 - NSI-189 - onabotulinumtoxin A - PH-10 - rapastinel - RP-5063 - SEP-363856 For more information visit http://www.researchandmarkets.com/research/m6...depressive
JNJ: 99.84 (+0.82), ITCI: 29.39 (-1.83), LLY: 84.97 (-0.71), GSK: 42.79 (+1.08), BMY: 64.37 (-0.29), ALKS: 67.49 (-1.90), CUR: 1.68 (-0.05)
Diabetic Neuropathy Therapeutics Pipeline Review 2015 - 16 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phhqrf/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Araim Pharmaceuticals Inc. - Astellas Pharma Inc. - Cebix Incorporated - Eli Lilly and Company - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Spinifex Pharmaceuticals Pty Limited - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. Drug Profiles - Antimunocel - ARA-290 - ASP-8477 - BBI-21007 - Biologic for Diabetic Nephropathy - BNV-222 - capsaicin - CBX-129801 - Cyndacel-M - Drug for Peripheral Neuropathic Pain and Diabetic Peripheral Neuropathy - EMA-401 - ketoprofen - Lpathomab - Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - NRD-135SE1 - NSI-566 - OMS-721 - Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - PF-05089771 - ranirestat - Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - RTU-1096 - Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Small Molecules for Diabetic Neuropathy - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy - VBY-285 - VM-202 For more information visit http://www.researchandmarkets.com/research/phhqrf/diabetic
PFE: 35.70 (+0.35), LLY: 84.97 (-0.71), VBAY: (), ACOR: 33.70 (-0.91), LPTN: 0.27 (-0.01), OMER: 16.12 (-0.24), CUR: 1.68 (-0.05)
Delving into Stem Cell Research and its Potential: 2015 Study
M2 - Mon Jun 29, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f9rhn9/delving_into_stem) has announced the addition of the "Delving into Stem Cell Research and its Potential" report to their offering. Stem cells are primal cells found in all multi-cellular organisms that retain the ability to renew themselves through mitotic cell division and can differentiate into a wide range of specialized cell types. As stem cells can be readily grown and transformed into specialized cells with characteristics consistent with cells of various tissues such as muscles or nerves through cell culture, their use in medical therapies has been proposed. In particular, embryonic cell lines, autologous embryonic stem cells generated through therapeutic cloning, and highly plastic adult stem cells from the umbilical cord blood or bone marrow are touted as promising candidates. There exists a widespread controversy over stem cell research that emanates from the techniques used in the creation and usage of stem cells. Human embryonic stem cell research is particularly controversial because, with the present state of technology, starting a stem cell line requires the destruction of a human embryo and/or therapeutic cloning. This research brings you an entire in-depth study of a very niche subject in the wide field of stem cells - Stem Cell Research and its Potential. The report looks at the various types of stem cells which exist and the different benefits each of them offer. The much-talked about embryonic stem cell research and adult stem cell research is discussed in-depth in the report. A separate section covers all the medical uses of stem cell research as well as exploring the potential of stem cell research and therapies. Challenges, barriers, benefits of stem cells, a look at the global approach to stem cell research, and an analysis of the leading players in this industry are what make this report a must-have! Key Topics Covered: A. Executive Summary B. Introduction to Stem Cells C. Looking into Stem Cell Research D. Potential of Stem Cell Research & Therapies E. Benefits of Stem Cell Therapies F. Barriers & Challenges in Stem Cell Research G. Stem Cell in Medical Use H. Trends in the Industry I. Funding for Stem Cell Research J. Global Approach to Human Stem Cell Research K. Industry Outlook L. Leading Players in Stem Cell Research M. Appendix N. Glossary of Terms Companies Mentioned - Amgen - Apceth Gmbh & Co. Kg - Athersys - Bioheart, Inc. - Biomagnetics Diagnostics Corporation - BioTime, Inc. - Brainstorm Cell Therapeutics Inc - Caladrius Biosciences Inc - Celera Corporation (Quest Diagnostics) - Cesca Therapeutics - Cryo-Cell International - CytoGenix, Inc. - Cytori Therapeutics Inc - Gamida Cell Ltd. - Geron Corporation - International Stem Cell Corporation (ISCO) - Microchip Technology Inc. - Neuralstem, Inc. - Ocata Therapeutics - Osiris Therapeutics, Inc. - StemCells Inc - Tigenix NV - Transition Therapeutics Inc. - Vericel Corporation For more information visit http://www.researchandmarkets.com/research/f9..._into_stem
KOOL: 0.74 (+0.01), OCAT: 4.27 (-0.15), VCEL: 3.38 (+0.03), MCHP: 42.83 (+0.17), TTHI: 2.21 (-0.03), OSIR: 21.21 (-0.29), AMGN: 169.71 (-3.03), CLBS: 1.76 (-0.03), BCLI: 3.21 (-0.06), CYTX: 0.45 (+0.01), GERN: 4.10 (-0.12), DGX: 73.15 (+1.03), CUR: 1.68 (-0.05)
Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market
PR Newswire - Mon Jun 29, 8:22AM CDT
Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced today that it has been approved for listing on the NASDAQ Capital Market under the symbol "CUR." The Company's common stock will continue to trade on the NYSE MKT until the market close on July 10, 2015. Trading on the NASDAQ Capital Market is expected to commence on July 13, 2015.
CUR: 1.68 (-0.05)
Hot Stock: Neuralstem, Shares Gain 5.9% (CUR)
Comtex SmarTrend(R) - Fri Jun 26, 10:16AM CDT
Neuralstem (AMEX:CUR) is one of today's best performing low-priced stocks, up 5.9% to $2.15 on 1.9x average daily volume. Neuralstem has traded 1.3 million shares thus far today, vs. average volume of 696,000 shares per day. The stock has outperformed the Dow (5.9% to the Dow's 0.4%) and outperformed the S&P 500 (5.9% to the S&P's 0.1%) during today's trading.
CUR: 1.68 (-0.05)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Jun 26, 8:11AM CDT
RGSE: 1.67 (+0.02), MU: 20.05 (+0.30), CLDN: 1.25 (unch), CBLI: 4.06 (+0.14), OCLS: 1.90 (+0.29), CUR: 1.68 (-0.05)
Neuralstem up 11% premarket on preclinical Alzheimer's data
Seeking Alpha - at Seeking Alpha - Fri Jun 26, 7:44AM CDT
CUR: 1.68 (-0.05)
Preclinical Data On Neuralstem's Genetically Modified HK532-IGF-1 Stem Cells In Alzheimer's Disease Presented At International Society For Stem Cell Research Annual Meeting
PR Newswire - Fri Jun 26, 6:32AM CDT
Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden http://neuralstem.com/published-papers. In the poster, researchers from the University of Michigan presented data that mice with an animal model of Alzheimer's disease (AD), transplanted with HK532-IGF-1 cells in the peri-hippocampus, performed better on hippocampal-dependent behavioral tasks than untreated mice, demonstrating both enhanced learning cognitive processes and memory consolidation. Researchers also reported a beta-amyloid plaque reduction in both the cortex and hippocampus of the mice that received the stem cells. Amyloid plaque is one of the two hallmarks of AD.
CUR: 1.68 (-0.05)
Lysosomal Storage Disorder Pipeline Review, H1 2015 - 15 Companies & 27 Drug Profiles
M2 - Thu Jun 11, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vxz52s/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - AngioChem Inc. - BBB Therapeutics B.V. - Chiesi Farmaceutici SpA - Fate Therapeutics, Inc. - Minoryx Therapeutics s.l. - Neuralstem, Inc. - Nuo Therapeutics, Inc. - Orphazyme ApS - Oxyrane Belgium NV - REGiMMUNE Corporation - Sagetis Biotech, S.L. - Sangamo BioSciences, Inc. - Synageva BioPharma Corp. - Ultragenyx Pharmaceutical Inc. Drug Profiles - 2B3-201 - ALD-601 - Chaperone-ERT Combinations - Delta-tocopherol - FT-1050 - ML-SA1 - NSI-566 - Orph-001 - Recombinant Enzyme for Farber Disease and Cystic Fibrosis - Recombinant Enzyme for LSD-2 Disease - Recombinant Enzyme for LSD-3 Disease - Recombinant Enzyme for LSD-4 Disease - Recombinant Enzyme for LSD-5 Disease - Recombinant Enzyme for Lysosomal Storage Disorder - Recombinant Enzyme to Activate LRP1 for Lysosomal Storage Disorder - RGI-5000 - SAG-002 - SBLSD-3 - SBLSD-4 - sebelipase alfa - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecules for GM1-gangliosidosis And Morquio B - Small Molecules for Lysosomal Storage Disorders - Stem Cell Therapy for Lysosomal Storage Disorder - UX-002 - UX-004 - ZA-011 For more information visit http://www.researchandmarkets.com/research/vx...al_storage
FATE: 7.18 (+0.01), GEVA: 238.60 (+2.80), SGMO: 8.83 (-0.37), FOLD: 16.60 (+0.12), CUR: 1.68 (-0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jun 10, 11:53AM CDT
CAPR: 4.50 (+0.06), TKAI: 13.25 (-0.56), XNET: 9.37 (+0.04), STRM: 2.60 (+0.09), GALT: 2.62 (+0.01), PBIB: 1.55 (+0.01), KUTV: 0.84 (+0.03), SHLD: 21.67 (-0.14), OCLS: 1.90 (+0.29), CCIH: 10.04 (+0.01), AOI: 21.80 (+0.09), TRCH: 1.36 (+0.01), VIMC: 10.71 (+0.26), CTP: 1.36 (unch), CRTN: 3.26 (-0.05), CPGI: 6.76 (-0.01), DCTH: 0.57 (+0.02), RCON: 1.69 (+0.02), MBLX: 3.30 (-0.02), CUR: 1.68 (-0.05)
Stock to Watch: Neuralstem Down 8.9% (CUR)
Comtex SmarTrend(R) - Wed Jun 10, 10:19AM CDT
Neuralstem (AMEX:CUR) is one of today's worst performing low-priced stocks, down 8.9% to $2.14 on 1.2x average daily volume. Thus far today, Neuralstem has traded 666,000 shares, vs. average volume of 577,000 shares per day. The stock has underperformed the Dow (-8.9% to the Dow's 1.1%) and underperformed the S&P 500 (-8.9% to the S&P's 1.0%) during today's trading.
CUR: 1.68 (-0.05)
Advanced Immunotherapy Clinical Trials for Cancer Therapies & Breast Cancer Treatments Focus on Developing Innovative Therapeutics & Gene-Silencing Cell Studies
PR Newswire - Wed Jun 10, 7:35AM CDT
Clinical Trials and Innovation Therapies continue to have the potential to drive the pharma and biotech sectors for the final six months of 2015 as forecasts point to the potential for another prosperous year. Cancer new treatments show promise of immuno-oncology therapies as further studies & trials continue to progress. Biotech Companies in focus today are Regen BioPharma, Inc. (OTC: RGBP), Sanofi SA (NYSE: SNY), Vical Incorporated (NASDAQ: VICL), RXi Pharmaceuticals Corporation (NASDAQ: RXII), Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) & Neuralstem, Inc. (NYSE: CUR)
VICL: 0.63 (-0.01), RXII: 0.43 (-0.02), RCPI: 1.24 (+0.04), SNY: 53.90 (+0.09), CUR: 1.68 (-0.05)
Global Anxiety Disorders Pipeline Review, H1 2015
M2 - Mon Jun 08, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6j3ln/anxiety_disorders) has announced the addition of the "Anxiety Disorders - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Adamed Sp. z o.o. - Addex Therapeutics Ltd - Avineuro Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - C4X Discovery Ltd - Catalyst Pharmaceutical Partners, Inc. - Concert Pharmaceuticals, Inc. - Edgemont Pharmaceuticals, LLC - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GW Pharmaceuticals plc - H. Lundbeck A/S - Heptares Therapeutics Ltd. - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Marinus Pharmaceuticals, Inc. - Merz Pharmaceuticals GmbH - MI.TO. Technology S.r.L. - Nanotherapeutics, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Newron Pharmaceuticals S.p.A. - Novartis AG - Nuvo Research Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/v6..._disorders
PFE: 35.71 (+0.36), LLY: 84.97 (-0.71), CNCE: 16.38 (-0.67), OMER: 16.12 (-0.24), JNJ: 99.84 (+0.82), NBIX: 49.75 (-2.17), CPRX: 5.01 (-0.22), MRNS: 14.96 (-0.02), ABBV: 71.37 (+0.14), ITCI: 29.39 (-1.83), CUR: 1.68 (-0.05), NVS: 103.80 (+1.01)
Global Ageing Therapeutics Pipeline Report 2015 - 4 Companies & 13 Drug Profiles
M2 - Fri Jun 05, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2hdjc/ageing_pipeline) has announced the addition of the "Ageing - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ageing, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ageing and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bioo Therapeutics - Neuralstem, Inc. - RepliCel Life Sciences, Inc. - RXi Pharmaceuticals Corporation Drug Profiles - BIOO-4 - BIOO-7 - Drugs for Ageing - metformin sirolimus - MG-29 - MMP-26051 - MMP-26052 - NSI-189 - RCS-01 - sirolimus - Small Molecule for Alzheimer's Disease and Ageing - Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - TM-5441 For more information visit http://www.researchandmarkets.com/research/c2...g_pipeline
CUR: 1.68 (-0.05)
Global Cerebral Palsy Therapeutics Pipeline Review, H1 2015 - Analysis of 7 Companies & 7 Drug Profiles
M2 - Fri Jun 05, 5:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfgn5k/cerebral_palsy) has announced the addition of the "Cerebral Palsy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cerebral Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Palsy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Allergan, Inc. - Cell Cure Neurosciences, Ltd. - Cellular Biomedicine Group, Inc. - CHA Bio & Diostech Co., Ltd. - K-Stemcell Co., Ltd. - Neuralstem, Inc. Drug Profiles - Astrostem - dalfampridine ER - NeurArrest - NSI-566 - onabotulinumtoxin A - Stem Cell Therapy for Cerebral Palsy - Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus For more information visit http://www.researchandmarkets.com/research/pf...bral_palsy
AGN: 336.87 (-2.63), ACOR: 33.70 (-0.91), CBMG: 27.49 (+2.72), CUR: 1.68 (-0.05)
Acute Spinal Cord Injury - Pipeline Review, H1 2015: 4 Companies & 7 Drug Profiles
M2 - Thu Jun 04, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4cpzq8/acute_spinal_cord) has announced the addition of the "Acute Spinal Cord Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Kringle Pharma, Inc. - Neuralstem, Inc. - Neuronax SAS Drug Profiles - AC-105 - BA-210 - Cell Therapy for Spinal Cord Injury - KP-100IT - NSI-566 - NX-210 - Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury For more information visit http://www.researchandmarkets.com/research/4c...pinal_cord
ACOR: 33.70 (-0.91), CUR: 1.68 (-0.05)
Next Week In Biotech: Baxter-Baxalta, BioLine RX Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri May 15, 8:00AM CDT
With the first-quarter earnings season in its final hours, the biotech calendar becomes fairly sparse next week. The earnings spigot goes almost completely dry, with only Israel-based BioLine RX (NASDAQ: BLRX ) providing an update Monday. With few...
IBB: 376.36 (-6.48), BLRX: 1.65 (-0.02), CUR: 1.68 (-0.05)
6 Stocks Under $10 Triggering Breakout Trades
at The Street - Thu Jul 23, 1:09PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
MBI: 6.33 (+0.14), MX: 8.45 (-0.17), JASO: 7.67 (+0.25), IDRA: 3.45 (-0.16), NPTN: 8.90 (-0.34), CUR: 1.68 (-0.05)
Court Rules That StemCells, Inc. Lacks Standing to Pursue Patent Infringement Suit
GlobeNewswire - Thu Jul 23, 12:42PM CDT
StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that the Company's patent infringement case, StemCells, Inc. v. Neuralstem, Inc., has been dismissed by the U.S. Federal District Court for the District of Maryland for lack of standing. The judge's decision was based solely on the grounds that a former associate of the named inventors on the six patents in the litigation, Drs. Samuel Weiss and Brent Reynolds, has an interest in the patents because, as a former colleague, he assisted with their early research.
STEM: 0.43 (+0.01), CUR: 1.68 (-0.05)
US District Court Rules In Favor Of Neuralstem In Patent Infringement Case
PR Newswire - Thu Jul 23, 6:45AM CDT
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the U.S. District Court for the District of Maryland dismissed StemCells, Inc.'s patent infringement case with prejudice in StemCells, Inc. v. Neuralstem, Inc. in favor of Neuralstem, on July 22, 2015.
CUR: 1.68 (-0.05)
Major Depressive Disorder Pipeline Review, H1 2015 - 37 Companies & 32 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6wpzn/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - Alkermes Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics plc - Edgemont Pharmaceuticals, LLC - Eli Lilly and Company - Euthymics Bioscience, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. Drug Profiles - (aripiprazole sertraline) - (samidorphan buprenorphine hydrochloride) - amitifadine - AN-788 - aripiprazole - AV-101 - AVP-786 - basimglurant - brexpiprazole - bupropion hydrochloride ER - cariprazine - CERC-301 - desvenlafaxine succinate SR - EDG-005 - edivoxetine - esketamine hydrochloride - INASTR-001 - ITI-007 - lurasidone hydrochloride - LY-03005 - LY-2940094 - MIN-117 - miR-135 - MSI-195 - NLF-NEU - NRX-1074 - NSI-189 - onabotulinumtoxin A - PH-10 - rapastinel - RP-5063 - SEP-363856 For more information visit http://www.researchandmarkets.com/research/m6...depressive
JNJ: 99.84 (+0.82), ITCI: 29.39 (-1.83), LLY: 84.97 (-0.71), GSK: 42.79 (+1.08), BMY: 64.37 (-0.29), ALKS: 67.49 (-1.90), CUR: 1.68 (-0.05)
Diabetic Neuropathy Therapeutics Pipeline Review 2015 - 16 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phhqrf/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Araim Pharmaceuticals Inc. - Astellas Pharma Inc. - Cebix Incorporated - Eli Lilly and Company - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Spinifex Pharmaceuticals Pty Limited - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. Drug Profiles - Antimunocel - ARA-290 - ASP-8477 - BBI-21007 - Biologic for Diabetic Nephropathy - BNV-222 - capsaicin - CBX-129801 - Cyndacel-M - Drug for Peripheral Neuropathic Pain and Diabetic Peripheral Neuropathy - EMA-401 - ketoprofen - Lpathomab - Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - NRD-135SE1 - NSI-566 - OMS-721 - Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - PF-05089771 - ranirestat - Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - RTU-1096 - Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Small Molecules for Diabetic Neuropathy - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy - VBY-285 - VM-202 For more information visit http://www.researchandmarkets.com/research/phhqrf/diabetic
PFE: 35.70 (+0.35), LLY: 84.97 (-0.71), VBAY: (), ACOR: 33.70 (-0.91), LPTN: 0.27 (-0.01), OMER: 16.12 (-0.24), CUR: 1.68 (-0.05)
Delving into Stem Cell Research and its Potential: 2015 Study
M2 - Mon Jun 29, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f9rhn9/delving_into_stem) has announced the addition of the "Delving into Stem Cell Research and its Potential" report to their offering. Stem cells are primal cells found in all multi-cellular organisms that retain the ability to renew themselves through mitotic cell division and can differentiate into a wide range of specialized cell types. As stem cells can be readily grown and transformed into specialized cells with characteristics consistent with cells of various tissues such as muscles or nerves through cell culture, their use in medical therapies has been proposed. In particular, embryonic cell lines, autologous embryonic stem cells generated through therapeutic cloning, and highly plastic adult stem cells from the umbilical cord blood or bone marrow are touted as promising candidates. There exists a widespread controversy over stem cell research that emanates from the techniques used in the creation and usage of stem cells. Human embryonic stem cell research is particularly controversial because, with the present state of technology, starting a stem cell line requires the destruction of a human embryo and/or therapeutic cloning. This research brings you an entire in-depth study of a very niche subject in the wide field of stem cells - Stem Cell Research and its Potential. The report looks at the various types of stem cells which exist and the different benefits each of them offer. The much-talked about embryonic stem cell research and adult stem cell research is discussed in-depth in the report. A separate section covers all the medical uses of stem cell research as well as exploring the potential of stem cell research and therapies. Challenges, barriers, benefits of stem cells, a look at the global approach to stem cell research, and an analysis of the leading players in this industry are what make this report a must-have! Key Topics Covered: A. Executive Summary B. Introduction to Stem Cells C. Looking into Stem Cell Research D. Potential of Stem Cell Research & Therapies E. Benefits of Stem Cell Therapies F. Barriers & Challenges in Stem Cell Research G. Stem Cell in Medical Use H. Trends in the Industry I. Funding for Stem Cell Research J. Global Approach to Human Stem Cell Research K. Industry Outlook L. Leading Players in Stem Cell Research M. Appendix N. Glossary of Terms Companies Mentioned - Amgen - Apceth Gmbh & Co. Kg - Athersys - Bioheart, Inc. - Biomagnetics Diagnostics Corporation - BioTime, Inc. - Brainstorm Cell Therapeutics Inc - Caladrius Biosciences Inc - Celera Corporation (Quest Diagnostics) - Cesca Therapeutics - Cryo-Cell International - CytoGenix, Inc. - Cytori Therapeutics Inc - Gamida Cell Ltd. - Geron Corporation - International Stem Cell Corporation (ISCO) - Microchip Technology Inc. - Neuralstem, Inc. - Ocata Therapeutics - Osiris Therapeutics, Inc. - StemCells Inc - Tigenix NV - Transition Therapeutics Inc. - Vericel Corporation For more information visit http://www.researchandmarkets.com/research/f9..._into_stem
KOOL: 0.74 (+0.01), OCAT: 4.27 (-0.15), VCEL: 3.38 (+0.03), MCHP: 42.83 (+0.17), TTHI: 2.21 (-0.03), OSIR: 21.21 (-0.29), AMGN: 169.71 (-3.03), CLBS: 1.76 (-0.03), BCLI: 3.21 (-0.06), CYTX: 0.45 (+0.01), GERN: 4.10 (-0.12), DGX: 73.15 (+1.03), CUR: 1.68 (-0.05)
Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market
PR Newswire - Mon Jun 29, 8:22AM CDT
Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced today that it has been approved for listing on the NASDAQ Capital Market under the symbol "CUR." The Company's common stock will continue to trade on the NYSE MKT until the market close on July 10, 2015. Trading on the NASDAQ Capital Market is expected to commence on July 13, 2015.
CUR: 1.68 (-0.05)
Hot Stock: Neuralstem, Shares Gain 5.9% (CUR)
Comtex SmarTrend(R) - Fri Jun 26, 10:16AM CDT
Neuralstem (AMEX:CUR) is one of today's best performing low-priced stocks, up 5.9% to $2.15 on 1.9x average daily volume. Neuralstem has traded 1.3 million shares thus far today, vs. average volume of 696,000 shares per day. The stock has outperformed the Dow (5.9% to the Dow's 0.4%) and outperformed the S&P 500 (5.9% to the S&P's 0.1%) during today's trading.
CUR: 1.68 (-0.05)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Jun 26, 8:11AM CDT
RGSE: 1.67 (+0.02), MU: 20.05 (+0.30), CLDN: 1.25 (unch), CBLI: 4.06 (+0.14), OCLS: 1.90 (+0.29), CUR: 1.68 (-0.05)
Neuralstem up 11% premarket on preclinical Alzheimer's data
Seeking Alpha - at Seeking Alpha - Fri Jun 26, 7:44AM CDT
CUR: 1.68 (-0.05)
Preclinical Data On Neuralstem's Genetically Modified HK532-IGF-1 Stem Cells In Alzheimer's Disease Presented At International Society For Stem Cell Research Annual Meeting
PR Newswire - Fri Jun 26, 6:32AM CDT
Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden http://neuralstem.com/published-papers. In the poster, researchers from the University of Michigan presented data that mice with an animal model of Alzheimer's disease (AD), transplanted with HK532-IGF-1 cells in the peri-hippocampus, performed better on hippocampal-dependent behavioral tasks than untreated mice, demonstrating both enhanced learning cognitive processes and memory consolidation. Researchers also reported a beta-amyloid plaque reduction in both the cortex and hippocampus of the mice that received the stem cells. Amyloid plaque is one of the two hallmarks of AD.
CUR: 1.68 (-0.05)
Lysosomal Storage Disorder Pipeline Review, H1 2015 - 15 Companies & 27 Drug Profiles
M2 - Thu Jun 11, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vxz52s/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - AngioChem Inc. - BBB Therapeutics B.V. - Chiesi Farmaceutici SpA - Fate Therapeutics, Inc. - Minoryx Therapeutics s.l. - Neuralstem, Inc. - Nuo Therapeutics, Inc. - Orphazyme ApS - Oxyrane Belgium NV - REGiMMUNE Corporation - Sagetis Biotech, S.L. - Sangamo BioSciences, Inc. - Synageva BioPharma Corp. - Ultragenyx Pharmaceutical Inc. Drug Profiles - 2B3-201 - ALD-601 - Chaperone-ERT Combinations - Delta-tocopherol - FT-1050 - ML-SA1 - NSI-566 - Orph-001 - Recombinant Enzyme for Farber Disease and Cystic Fibrosis - Recombinant Enzyme for LSD-2 Disease - Recombinant Enzyme for LSD-3 Disease - Recombinant Enzyme for LSD-4 Disease - Recombinant Enzyme for LSD-5 Disease - Recombinant Enzyme for Lysosomal Storage Disorder - Recombinant Enzyme to Activate LRP1 for Lysosomal Storage Disorder - RGI-5000 - SAG-002 - SBLSD-3 - SBLSD-4 - sebelipase alfa - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecules for GM1-gangliosidosis And Morquio B - Small Molecules for Lysosomal Storage Disorders - Stem Cell Therapy for Lysosomal Storage Disorder - UX-002 - UX-004 - ZA-011 For more information visit http://www.researchandmarkets.com/research/vx...al_storage
FATE: 7.18 (+0.01), GEVA: 238.60 (+2.80), SGMO: 8.83 (-0.37), FOLD: 16.60 (+0.12), CUR: 1.68 (-0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jun 10, 11:53AM CDT
CAPR: 4.50 (+0.06), TKAI: 13.25 (-0.56), XNET: 9.37 (+0.04), STRM: 2.60 (+0.09), GALT: 2.62 (+0.01), PBIB: 1.55 (+0.01), KUTV: 0.84 (+0.03), SHLD: 21.67 (-0.14), OCLS: 1.90 (+0.29), CCIH: 10.04 (+0.01), AOI: 21.80 (+0.09), TRCH: 1.36 (+0.01), VIMC: 10.71 (+0.26), CTP: 1.36 (unch), CRTN: 3.26 (-0.05), CPGI: 6.76 (-0.01), DCTH: 0.57 (+0.02), RCON: 1.69 (+0.02), MBLX: 3.30 (-0.02), CUR: 1.68 (-0.05)
Stock to Watch: Neuralstem Down 8.9% (CUR)
Comtex SmarTrend(R) - Wed Jun 10, 10:19AM CDT
Neuralstem (AMEX:CUR) is one of today's worst performing low-priced stocks, down 8.9% to $2.14 on 1.2x average daily volume. Thus far today, Neuralstem has traded 666,000 shares, vs. average volume of 577,000 shares per day. The stock has underperformed the Dow (-8.9% to the Dow's 1.1%) and underperformed the S&P 500 (-8.9% to the S&P's 1.0%) during today's trading.
CUR: 1.68 (-0.05)
Advanced Immunotherapy Clinical Trials for Cancer Therapies & Breast Cancer Treatments Focus on Developing Innovative Therapeutics & Gene-Silencing Cell Studies
PR Newswire - Wed Jun 10, 7:35AM CDT
Clinical Trials and Innovation Therapies continue to have the potential to drive the pharma and biotech sectors for the final six months of 2015 as forecasts point to the potential for another prosperous year. Cancer new treatments show promise of immuno-oncology therapies as further studies & trials continue to progress. Biotech Companies in focus today are Regen BioPharma, Inc. (OTC: RGBP), Sanofi SA (NYSE: SNY), Vical Incorporated (NASDAQ: VICL), RXi Pharmaceuticals Corporation (NASDAQ: RXII), Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) & Neuralstem, Inc. (NYSE: CUR)
VICL: 0.63 (-0.01), RXII: 0.43 (-0.02), RCPI: 1.24 (+0.04), SNY: 53.90 (+0.09), CUR: 1.68 (-0.05)
Global Anxiety Disorders Pipeline Review, H1 2015
M2 - Mon Jun 08, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6j3ln/anxiety_disorders) has announced the addition of the "Anxiety Disorders - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Adamed Sp. z o.o. - Addex Therapeutics Ltd - Avineuro Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - C4X Discovery Ltd - Catalyst Pharmaceutical Partners, Inc. - Concert Pharmaceuticals, Inc. - Edgemont Pharmaceuticals, LLC - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GW Pharmaceuticals plc - H. Lundbeck A/S - Heptares Therapeutics Ltd. - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Marinus Pharmaceuticals, Inc. - Merz Pharmaceuticals GmbH - MI.TO. Technology S.r.L. - Nanotherapeutics, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Newron Pharmaceuticals S.p.A. - Novartis AG - Nuvo Research Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/v6..._disorders
PFE: 35.71 (+0.36), LLY: 84.97 (-0.71), CNCE: 16.38 (-0.67), OMER: 16.12 (-0.24), JNJ: 99.84 (+0.82), NBIX: 49.75 (-2.17), CPRX: 5.01 (-0.22), MRNS: 14.96 (-0.02), ABBV: 71.37 (+0.14), ITCI: 29.39 (-1.83), CUR: 1.68 (-0.05), NVS: 103.80 (+1.01)
Global Ageing Therapeutics Pipeline Report 2015 - 4 Companies & 13 Drug Profiles
M2 - Fri Jun 05, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2hdjc/ageing_pipeline) has announced the addition of the "Ageing - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ageing, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ageing and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bioo Therapeutics - Neuralstem, Inc. - RepliCel Life Sciences, Inc. - RXi Pharmaceuticals Corporation Drug Profiles - BIOO-4 - BIOO-7 - Drugs for Ageing - metformin sirolimus - MG-29 - MMP-26051 - MMP-26052 - NSI-189 - RCS-01 - sirolimus - Small Molecule for Alzheimer's Disease and Ageing - Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - TM-5441 For more information visit http://www.researchandmarkets.com/research/c2...g_pipeline
CUR: 1.68 (-0.05)
Global Cerebral Palsy Therapeutics Pipeline Review, H1 2015 - Analysis of 7 Companies & 7 Drug Profiles
M2 - Fri Jun 05, 5:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfgn5k/cerebral_palsy) has announced the addition of the "Cerebral Palsy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cerebral Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Palsy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Allergan, Inc. - Cell Cure Neurosciences, Ltd. - Cellular Biomedicine Group, Inc. - CHA Bio & Diostech Co., Ltd. - K-Stemcell Co., Ltd. - Neuralstem, Inc. Drug Profiles - Astrostem - dalfampridine ER - NeurArrest - NSI-566 - onabotulinumtoxin A - Stem Cell Therapy for Cerebral Palsy - Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus For more information visit http://www.researchandmarkets.com/research/pf...bral_palsy
AGN: 336.87 (-2.63), ACOR: 33.70 (-0.91), CBMG: 27.49 (+2.72), CUR: 1.68 (-0.05)
Acute Spinal Cord Injury - Pipeline Review, H1 2015: 4 Companies & 7 Drug Profiles
M2 - Thu Jun 04, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4cpzq8/acute_spinal_cord) has announced the addition of the "Acute Spinal Cord Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Kringle Pharma, Inc. - Neuralstem, Inc. - Neuronax SAS Drug Profiles - AC-105 - BA-210 - Cell Therapy for Spinal Cord Injury - KP-100IT - NSI-566 - NX-210 - Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury For more information visit http://www.researchandmarkets.com/research/4c...pinal_cord
ACOR: 33.70 (-0.91), CUR: 1.68 (-0.05)
Next Week In Biotech: Baxter-Baxalta, BioLine RX Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri May 15, 8:00AM CDT
With the first-quarter earnings season in its final hours, the biotech calendar becomes fairly sparse next week. The earnings spigot goes almost completely dry, with only Israel-based BioLine RX (NASDAQ: BLRX ) providing an update Monday. With few...
IBB: 376.36 (-6.48), BLRX: 1.65 (-0.02), CUR: 1.68 (-0.05)
(0)
(0)